FDA Greenlights VUEWAY® for Use in Neonates and Infants, Improving MRI Safety The FDA has approved Bracco's VUEWAY® solution for pediatric MRIs, offering a safer low-dose contrast option for neonates, ensuring image quality while reducing gadolinium exposure.

FDA Greenlights VUEWAY® for Use in Neonates and Infants, Improving MRI Safety #Bracco #VUEWAY #gadopiclenol

Guerbet's Elucirem™ Approved for Pediatric MRI with Half-Dose Gadolinium Use Guerbet's Elucirem™ (gadopiclenol) receives FDA approval for pediatric MRI use, including term neonates, with half the conventional gadolinium dosage.

Guerbet's Elucirem™ Approved for Pediatric MRI with Half-Dose Gadolinium Use #USA #Princeton #gadopiclenol #Guerbet #Elucirem

New Indication for Pediatric Use of Guerbet's Elucirem™ Approved by EU Commission Guerbet's Elucirem™ receives European Commission approval for pediatric MRI use, offering a reduced gadolinium dose for infants. A significant advancement in medical imaging.

New Indication for Pediatric Use of Guerbet's Elucirem™ Approved by EU Commission #France #gadopiclenol #Guerbet #Villepinte #Elucirem

Guerbet's Elucirem™ Secures EU Approval for Pediatric Use with Half-Dose Solution Guerbet has received European Commission approval for Elucirem™, a gadolinium-based contrast agent for infants, enabling half-dose MRIs while ensuring patient safety.

Guerbet's Elucirem™ Secures EU Approval for Pediatric Use with Half-Dose Solution #France #gadopiclenol #Elucirem™ #Guerbet #Villepinte

Guerbet's Elucirem™ Receives New Approval for Pediatric Use in Europe Guerbet announces the European approval of Elucirem™, a low-dose gadolinium contrast agent, now safe for infants and enhancing MRI imaging.

Guerbet's Elucirem™ Receives New Approval for Pediatric Use in Europe #None #gadopiclenol #Elucirem™ #Guerbet

European Commission Approves New Pediatric Indication for Elucirem™ (Gadopiclenol) from Guerbet Guerbet announces the European Commission's approval of a new pediatric indication for Elucirem™, enabling its safe use in infants for MRI procedures.

European Commission Approves New Pediatric Indication for Elucirem™ (Gadopiclenol) from Guerbet #France #gadopiclenol #Elucirem™ #Guerbet #Villepinte

European Commission Grants Pediatric Use Approval for Vueway® (gadopiclenol) by Bracco Imaging Bracco Imaging announces that the European Commission has extended Vueway®'s marketing authorization for pediatric patients under two, a significant advancement in diagnostic imaging.

European Commission Grants Pediatric Use Approval for Vueway® (gadopiclenol) by Bracco Imaging #Italy #Milan #Bracco_Imaging #VUEWAY #gadopiclenol

European Commission Approves Expanded Use of Vueway® for Pediatric Patients Bracco Imaging has announced that Vueway® (gadopiclenol) has received approval for use in pediatric patients under 2 in the EU, enhancing diagnostic options.

European Commission Approves Expanded Use of Vueway® for Pediatric Patients #None #Bracco_Imaging #VUEWAY #gadopiclenol

European Medicines Agency Approves Vueway® for Young Children Under 2 Bracco Imaging's Vueway® (gadopiclenol) has received a favorable opinion from the European Medicines Agency for use in pediatric patients under two years of age.

European Medicines Agency Approves Vueway® for Young Children Under 2 #Italy #Milan #Bracco_Imaging #VUEWAY #gadopiclenol